web analytics

MS Stem Cell Therapy NG01 Gets FDA Clearance for Expanded Access in Progressive MS

Illustration of a stem cell therapy vial and a myelinated neuron, representing NG01 expanded access for progressive MS

An experimental MS stem cell therapy called NG01 can now be requested for some people with progressive multiple sclerosis who cannot join a clinical trial. NeuroGenesis Bio announced on Nov. 17 that the U.S. Food and Drug Administration has cleared its expanded access program, and the first patient was scheduled for a bone marrow draw at the University of Miami the same day.

This matters because progressive MS has few options. Current approved drugs mainly act on the immune system in the blood and do little to repair nerve damage or reverse disability. NG01 is made from each patient’s own bone marrow cells and injected into the spinal fluid. It is still investigational and not FDA-approved.

What the FDA Cleared

Expanded access, often called compassionate use, is an FDA pathway that lets doctors request an unapproved therapy for patients with serious diseases and no satisfactory alternatives, outside a formal trial. According to the company, treating physicians can now request NG01 for eligible U.S. patients with progressive MS who are not able to enroll in its studies.

The program starts at the University of Miami Miller School of Medicine under neurologist Dr. Flavia Nelson, who is also the lead investigator for the company’s upcoming Phase 2b trial. Additional U.S. sites are expected later. A $500,000 gift from the Mendoza Family Fund, created with the National MS Society, supports the Miami program, and NeuroGenesis says it is funding a significant portion of the costs itself. The release says NG01 received the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation for secondary progressive MS earlier this year.

“NG01 takes a different approach from the therapies available to us today,” Dr. Nelson said in the company’s announcement, adding that it is designed to act in the brain and spinal cord “rather than on the peripheral immune system alone.”

How This MS Stem Cell Therapy Works

The company describes NG01 as an autologous “neuronal threshold” cell therapy: the patient’s own bone marrow cells are grown and processed so they release growth and anti-inflammatory factors, then delivered by intrathecal (spinal) injection to bypass the blood-brain barrier. The goal is to calm inflammation inside the central nervous system and support myelin repair. For background on cell types, see our guide What Are Stem Cells?

Stem Cell Tracker Analysis

We went back to the published trial data and the federal trial registry. Here is what the press coverage leaves out.

  • The key trial was small and mixed MS types. The main evidence is a 48-patient randomized, double-blind, placebo-controlled study from Hadassah Medical Center in Israel, published in Brain in 2020 (Petrou et al.). It enrolled people with active progressive MS and tested bone marrow mesenchymal stem cells given either into the spinal fluid or into a vein.
  • The reported numbers were strong but need replication. In the published abstract, treatment failure occurred in 6.7% of the intrathecal group and 9.7% of the intravenous group, versus 41.9% with sham treatment. Patients with no evidence of disease activity were 58.6% (intrathecal) versus 9.7% (sham). No serious treatment-related safety problems were reported. A trial this size can show a signal, not prove a benefit.
  • The publication calls it mesenchymal stem cells. The 2020 paper describes the product as autologous mesenchymal stem cells; the company now markets it as a “neuronal threshold cell therapy.” Readers comparing reports should know these refer to the same program.
  • The U.S. trial listing is out of date. The Phase 2b study, NCT06961383, plans about 45 participants with secondary progressive MS at the University of Miami and Hadassah. Its primary goals are improvement in walking speed on the Timed 25-Foot Walk over 12 months and the rate of treatment-related side effects. The registry still lists it as “not yet recruiting” with an estimated October 2025 start and was last updated in May 2025; the company now says the trial is expected to begin in the first half of 2027.
  • The ALS figures are uncontrolled. The release also cites long survival in a 20-patient ALS study, but that study had no control group, so it cannot show the therapy caused the outcome.

Stem cell treatments for MS are not new. Aggressive approaches such as autologous hematopoietic stem cell transplantation (AHSCT) reset the immune system and work best in active relapsing disease. NG01 is a different, less intensive approach aimed at progressive disease. For more context on regulatory designations like RMAT, see our coverage of nula-cel’s RMAT designation, and our explainer Stem Cells Explained.

What This Means for Patients

For people living with progressive MS, this is a real but narrow opening. NG01 is not approved, and expanded access is not a shortcut to a proven treatment. It is meant for patients with serious disease who have no satisfactory alternatives and cannot join the upcoming Phase 2b trial. For now, access runs through the University of Miami, with more U.S. sites expected.

The evidence so far comes from small studies, mostly at one center in Israel. A larger controlled trial is still needed to confirm whether NG01 slows or improves disability. A realistic path to any approval is several years away.

If you are interested, talk with your neurologist, who would need to request the therapy. The company posts eligibility updates at neurogenesis-cell.com/policy. Be cautious of private clinics offering “stem cell treatments for MS” for cash outside regulated programs; see our guide to stem cell clinic red flags. This is not personal medical advice.

Sources

Reviewed by T. Lancaster, Editor. Stem Cell Tracker uses AI tools to help research and draft stories; see our Editorial Policy. This article is for education only and is not medical advice.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Scroll to Top